A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

Abstract

PURPOSE This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy in patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN Enrolled in six cohorts, patients were given arsenic trioxide (0.125 or 0.250 mg/kg… (More)

Topics

6 Figures and Tables

Cite this paper

@article{Berenson2007API, title={A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.}, author={James R Berenson and Jeffrey V. Matous and Regina A. Swift and Russell Mapes and Blake Morrison and Howard S Yeh}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2007}, volume={13 6}, pages={1762-8} }